The new coronavirus special medicine is here: it can reduce the viral load by 99.9%
For this reason, Griffith University, Queensland, Australia The Sri Lanka Institute of Health and several research and treatment centers such as cancer and diabetes in the United States have developed an experimental antiviral therapy to treat patients with new coronary pneumonia.
The new antiviral therapy is called siRNA (small interfering RNA), based on RNA gene silencing technology. The therapy can directly attack the viral genome, thereby preventing virus replication.
Queensland Menzies Health Research According to Nigel McMillan, siRNA therapy can reduce viral load by 99.9%. In addition, lipid nanoparticles (a submicron drug delivery system) can deliver drugs to lung cells , So that the tissue virus replicates.
This therapy has been verified in mouse experiments, which not only greatly improves the survival rate of experimental mice, but also reduces the related harm caused by diseases. In addition, in the treated mice, no virus was detected in the lungs.
It is worth mentioning that this therapy can be used Treat all β-coronaviruses, such as SARS virus and new coronavirus, and any virus variants that may appear in the future.
Macmillan said that we also found that these nanoparticles can be stored at 4°C room temperature for more than 12 months. Therefore, siRNA nanoparticle preparations can be used as a drug for the treatment of patients with new coronary pneumonia, or directly Targeting viral genomes for future coronavirus infections.